Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®

@inproceedings{Frevert2010ContentOB,
  title={Content of Botulinum Neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®},
  author={J{\"u}rgen Frevert},
  booktitle={Drugs in R&D},
  year={2010}
}
BACKGROUND Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective treatment of neurologic disorders such as cervical dystonia, blepharospasm, or spasticity, as well as other indications such as axillary and palmar hyperhidrosis, and urologic disorders. OBJECTIVE To determine the amount of BoNT/A protein present in pharmaceutical preparations of Botox®, Dysport®, and Xeomin®, which are identical with Vistabel®, Azzalure®, and Bocouture… CONTINUE READING
48 Citations
24 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use

  • N Panjwani, R O’Keeffe, A. Pickett
  • Botulinum J
  • 2008
Highly Influential
6 Excerpts

Comparison of the efficacy and safety of NT 201, free of complexing proteins, with a licensed botulinum toxin type A in the treatment of glabellar frown lines

  • G. Sattler
  • IMCAS conference;
  • 2010
2 Excerpts

Improved botulinum toxin composition. US Patent application 2007/0025019 [online]. Available from URL: http://www.wipo.int/pctdb/en/wo.jsp?wo=2007016018&IA= US2006028603&DISPLAY=DESC

  • TJ Hunt
  • 2010
1 Excerpt

Botulinum toxintherapeutic clinical practice and science

  • J Jankovic, A Albanese, MZ Attassi
  • Philadelphia (PA): Saunders Elsevier,
  • 2009
1 Excerpt

Properties of pharmaceutical products of botulinum neurotoxins (chapter 32)

  • H. Bigalke
  • Philadelphia (PA): Saunders Elsevier,
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…